First Brands Group debt targeted by Apollo Global Management - report
Investing.com - H.C. Wainwright has reiterated its Buy rating and $8.00 price target on ImmunityBio Inc (NASDAQ:IBRX), currently trading at $2.57, following the company’s presentation of updated clinical data at the 2025 IASLC World Conference on Lung Cancer. The $2.43 billion market cap company has seen analyst targets ranging from $5 to $24, according to InvestingPro data.
The data came from the Phase 2 QUILT-3.055 trial of ANKTIVA (nogapendekin alfa inbakicept, NAI) in advanced non-small cell lung cancer patients who had developed resistance to checkpoint inhibitors. Results showed 60% of treated patients experienced reversal of lymphopenia, while 80% exceeded or maintained an absolute lymphocyte count (ALC) of 1,200 cells/µL. The company’s strong liquidity position, with a current ratio of 4.11, supports its ongoing clinical development programs.
These improvements translated to survival benefits, with patients achieving ALC >1,200 living a median of 15.8 months compared to 11.5 months for those who did not. Patients sustaining ALC ≥1,500 demonstrated a 21.1-month median overall survival, with some surviving beyond four years.
The research firm noted that ANKTIVA is positioning itself as a lymphorestorative therapy addressing treatment-induced lymphopenia, a condition affecting more than half of patients with advanced malignancies and historically considered an immutable negative prognostic factor.
H.C. Wainwright highlighted that ANKTIVA is "rapidly establishing itself as a versatile immunorestorative therapy" with FDA approval already secured and potential applications across multiple treatment regimens and malignancies. InvestingPro analysis shows the stock has demonstrated strong momentum with an 8.44% return over the last week, while maintaining low market correlation with a beta of -0.07. Subscribers can access additional insights and 5 more exclusive ProTips about IBRX’s financial health and market positioning.
In other recent news, ImmunityBio, Inc. announced promising early results from its pilot study on a chemotherapy-free treatment for recurrent glioblastoma, a challenging brain cancer. All five patients in the study achieved 100% disease control using a combination of ANKTIVA, NK cell therapy, and the Optune Gio Tumor Treating Fields device. Among these patients, three showed tumor response, with two achieving near complete responses, while the remaining two maintained stable disease. Additionally, ImmunityBio launched a Phase 2 clinical trial to evaluate ANKTIVA for treating long COVID, aiming to recruit up to 40 participants. The study will primarily focus on the safety of subcutaneous administration of ANKTIVA.
In another development, the company reported encouraging results from its QUILT-106 Phase I trial targeting Waldenstrom macroglobulinemia, a type of non-Hodgkin lymphoma. The first two patients treated with the CD19 CAR-NK natural killer cell therapy achieved complete responses, with one maintaining remission for six months. The therapy showed effectiveness both as a monotherapy and in combination with rituximab. These advancements reflect ImmunityBio’s ongoing efforts in developing innovative treatments for challenging medical conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.